natgillin/translations-raw huggingface dataset:
delumping an extragranular lubricant using a screen or mill and blending with granules from the step (5); 
uklanjanje grudica iz ekstragranularnog lubrikanta uporabom sita ili mlina i miješanje sa granulama iz koraka (4);
Ce 0.2; the remainder being Fe and unavoidable impurities, the ferrite content being 30- 70 % by volume. 
0-02; ostatak čini željezo i neizbježne primjese, a volumni udio ferita je 30-70%.
The compounds of the present invention may be prepared by methods such as those found in the exemplary processes described in the following schemes and working examples, as well as relevant published literature procedures that are used by one skilled in the art. 
POSTUPCI PRIPREME Spojevi prikazanog izuma mogu se pripremiti primjenom postupaka kao što su oni koji su prikazani na slijedećim prikazima i radnim primjerima, jednako kao i relevantnim postupcima iz objavljenje literature što koriste osobe iz struke.
Subjecting the eluate of the hydrophobic interaction chromatography to reverse phase chromatography. 
Nanošenje eluata iz koraka (c) na kolonu za kromatografiju hidrofobnih interakcija;
a moisture content of from 0.2 wt-% to 0.6 wt-% based on a total dry weight of the crumbles. The crumbles according to claim 1, wherein the crumbles have: 
udio vlage od 0.2 tež.-% do 0.6 tež.-%, poželjno od 0.2 tež.-% do 0.4 tež.-% i najpoželjnije od 0.25 tež.-% do 0.35 tež.-% bazirano na ukupnoj suhoj težini mrvica.
The salt according to claim 2, further characterized in that the compound has an X-ray powder diffraction pattern containing at least peaks with 2-theta values at 8.9°, 10.9° and 18° measured using CuKa radiation. 
Sol prema zahtjevu 2, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8.9%, 10,9% 18* mjereno korištenjem CuKa zračenja.
The use according to claim 7, wherein the infusion time for intravenous injection is up to 6 hours for said effective therapeutic amount of PLD and up to 24 hours for said effective therapeutic amount of ET-743. 
Primjena prema patentnom zahtjevu 7, naznačena time što je vrijeme infuzije za intravenoznu injekciju do 6 sati za navedenu efikasnu terapeutsku količinu PLD i do 24 sata za navedenu efikasnu terapeutsku količinu ET-743.
In one aspect of such use, said influenza infection is caused by an influenza virus that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak (see WO 2007/045674 and the tables therein). 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 5, naznačeni time da je navedena infekcija influence uzrokovana sa virusom influence koji se povezuje sa izbijanjem pandemije, ili ima potencijal da se poveže sa izbijanjem pandemije.
The pharmaceutical composition of claim 3 or 4, wherein the at least one additional therapeutic agent is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, other drugs for treating HCV, and combinations thereof. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 8, gdje sastav sadrži dva ili tri dodatna terapijska agensa izabrana od inhibitora HIV proteaze, ne-nukleozidnih inhibitora HIV reverzne transkriptaze, nukleozidnih inhibitoria HIV reverzne transkriptaze, nukleotidnih inhibitoria HIV reverzne transkriptaze i inhibitora HIV integraze. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 9, gdje je najmanje jedan dodatni terapijski agens izabran iz grupe koja se sastoji od spojeva koji inhibiraju HIV proteaze.
reacting a compound of the formula R-CN (II a), wherein R comprises a protected reactive group, with an azide of formula RIR2MN3 (IIb), and 
reakciju spoja formule R-CN (II a), gdje R sadrži zaštićenu reaktivnu skupinu, s azidom formule R1R2MN3 (II b), te
reacting compound 104 with RX, wherein R is Me and X is a halide, in the presence of a base to provide compound 105 . 
reakciju spoja 104 i RX, pri čemu je R Me, a X je halid, u prisutnosti baze za dobivanje spoja 105.
A kit comprising a vaccine combination product of any one of claims 10-13. The composition of claim 9, or the vaccine combination product of any one of claims 10-13, for use in inducing an immune response against HIV in a subject. 
Pripravak prema patentnom zahtjevu 12 ili kombinacija cjepiva prema patentnom zahtjevu 13 naznačena time što je za uporabu za induciranje imunološkog odgovora protiv virusa ljudske imunodeficijencije (HIV) kod subjekta kojem je to potrebno.
The composition of claim 3 having, at T2 no more than, on average, 10,000 subvisible particles per mL having a size greater than 5 um. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja ima, u prosjeku, ne više od 10 000 čestica ispod granice vidljivosti po mL, koje imaju veličinu veću od 5 um.
Group 2: Vehicle control group (2 ml/kg i.p.) 
Skupina 2: podloga, kontrolna skupina (2 ml/kg i.p.)
In the opposite direction of rotation of the drive gear to close the neck ring arms, the formally non-load transmitting idler gear becomes the load transmitting gear, and vice versa. 
U suprotnom smjeru vrtnje pogonskog zupčanika, kojim se zatvaraju hvataljke izdanka kalupa, zupčanik, koji prije nije prenosi moment, sada ga prenosi, i obratno.
A method of treating a respiratory condition chosen from asthma and chronic obstructive pulmonary disease, comprising administering a pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier; wherein the pharmaceutical composition is in a dosage from which provides: a) a metered nominal dose of aclidinium equivalent to 400 micrograms plus/minus 10% of aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide, by inhalation to a patient in need of such treatment. The method of claim 15, further comprising administering an effective amount of at least one additional active agent chosen from B2-agonists, PDE IV inhibitors, and corticosteroids. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu u liječenju kronične opstruktivne plućne bolesti u bolesnika kojem je potrebno takvo liječenje, pri čemu se spomenuta primjena sastoji od davanja inhalacijom jednom ili dvaput dnevno odmjerene nominalne doze aklidinija jednake 400 mikrograma (plus/minus 10 %) aklidinijevog bromida. Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 11, pri čemu se spomenuta primjena sastoji od davanja farmaceutskog pripravka prema bilo kojem zahtjevu od 1 do 10. Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 11 ili 12, pri čemu se spomenuta primjena dalje sastoji od davanja djelotvorne količine jedne ili više dodatnih aktivnih tvari odabranih iz B2 agonista, inhibitora PDE IV i kortikosteroida.
A pharmaceutical composition comprising a compound of claim 18 and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji obuhvaća spoj prema zahtjevu 18 i bar jedan farmaceutski prihvatljivi nosač.
A method according to claim 1, wherein R2a represents hydrogen or fluoro. 
Spoj sukladno patentnom zahtjevu 1 ili 2 naznačeno time, da R2a predstavlja vodik ili floro.
The immobilised phospho-peptide product of the reaction was detected by immunological methods. 
Imobilizrani fosfo-peptidni produkt reakcije odredi se imunološkim postupcima.
The pharmaceutical formulation of claim 7 for use in a method of treating HER2 positive cancer in a patient, wherein in the method the pharmaceutical formulation of claim 7 is administered to the patient in an amount effective to treat the cancer. 
Farmaceutska formulacija prema zahtjevu 7, naznačena time, da se upotrebljava u postupku liječenja pacijenta od raka pozitivnog na HER2, pri čemu se u tom postupku farmaceutska formulacija prema zahtjevu 7, daje pacijentu u količini koja je djelotvorna za liječenje raka.
A method of treating through anti-inflammatory, analgesic, and antipyretic activity a condition selected from the group consisting of: rheumatoid arthritis, juvenile rheumatoid arthritis, Still's disease, ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies, non-articular rheumatic conditions, frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis, swollen joints, low back pain and other disorders of the muscles, bones and tendons, soft tissue injuries, sprains and strains, relief of mild to moderate pain, dysmenorrhoea, dental and post-operative pain, headache, migraine headache, pain and fever in hospitalized patients, pyrexia in children over one year of age, pericarditis and patent ductus arteriosus (PDA), the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 1 . 
Pripravak prema bilo kojem od zahtjeva 1 do 8, za njegovu uporabu u liječenju reumatoidnog artritisa (uključujući juvenilni reumatoidni artritis ili Stillovu bolest), ankiloznog spondilitisa, osteoartritisa i drugih ne-reumatoidnih (seronegativnih) artropatija, izvanzglobnih reumatičnih stanja, smrznutog ramena (kapsulitis), burzitisa, tendinitisa, tenosinovitisa, oteklih zglobova, boli u donjem dijelu leđa 1 drugih poremećaja mišića, kostiju i tetiva; iščašenja 1 uganuća, dismenoreje, dentalne i postoperativne boli, simptomatske glavobolje uključujući migrenu, boli i temperature u hospitaliziranih bolesnika, temperature u djece starije od jedne godine, perikarditisa i perzistentnog ductus arteriosus (Patent ductus arteriosus (PDA), taj pripravak se koristi bez razrjeđivanja.
The compound of claim 1 having formula (VI) or a pharmaceutically acceptable salt thereof. 
HR P20140174 T1 ili njegova farmaceutski prihvatljiva sol; ili formulu (VI) N-NH
wherein R4 and R5 are, independently, hydrogen or a straight or branched C1-C6alkyl group optionally substituted by one or more hydroxy or C1-C6 alkoxy groups and Z is a halogen atom or any suitable leaving group; so as to obtain a compound of formula (4) 
(3) pri čemu R4 i Rs su, isti ili međusobno različiti, vodik ili ravna ili razgranata skupina C,-Cg alkil koja je proizvoljno supstituirana sa jednom ili više hidroksi ili C,-C4 alkoksi skupina i Z je halogeni atom ili bilo koja pogodna odlazeća skupina; tako da se dobije spoj s formulom (4)
A medicament comprising glatiramer acetate for use in treating a patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament is to be administered in a regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu u liječenju čovjeka kao pacijenta koji pati od relapsirajućeg oblika multiple skleroze, naznačen time, da se daje u režimu od tri supkutane injekcije dozom od po 40 mg glatiramer acetata svakog tjedna s barem jednim danom između svake supkutane injekcije i u čemu farmaceutski sastav nadalje sadrži manitol i ima pH u području od 5,5 do 7,0.
a controlled positioning apparatus having a clamping means for holding the vessel, which positioning apparatus is adapted for positioning the vessel at a pre-determined position in relation to the shear-force generator. 
Upotreba prema jednom od zahtjeva 11 do 15, naznačeno time da uređaj sadrži kontrolirani aparat za pozicioniranje koji ima sredstva za stezanje (50) za držanje reakcijskog nositelja (31), koji aparat za pozicioniranje je prilagođen za pozicioniranje reakcijskog nositelja (31) na predeterminiranim pozicijama u odnosu na generator sile smicanja.
wherein R1, R2, R4, R5 and R6 are as defined above, with a compound represented by the formula (III): 
predstavljen formulom (II): gdje su R', R', R*, RŽi R* gore definirani, sa spojem predstavljenim formulom (III):
Moreover, the use of this ingredient results in a composition that provides a degree of immediate water-proofing capability and thus obviates a waiting period before entering the water that is recommended with the use of conventional water-proof compositions. 
Nadalje, upotreba ovog sastojka daje pripravak koji pruža stupanj neposredne sposobnosti za vodootpornost i tako uklanja period čekanja prije ulaska u vodu, koji je preporučen kod upotrebe uobičajenih vodootpornih pripravaka.
The tire vulcanizer (1) according to claim 5, wherein the post-cure inflator (4) is fixed to the vulcanizer main body (3). 
Vulkanizator gume (1) u skladu s patentnim zahtjevom 5, naznačen time, da je uređaj za napuhavanje (4) fiksiran na glavno tijelo vulkanizatora (3).
or a pharmaceutically acceptable salt thereof, wherein the method comprises resolving a compound of formula (I): 
IZ ili njegove farmaceutski prihvatljive soli; i b) obradi spoja formule (8):
The organic portions are washed with brine, dried (Na2SO4) and concentrated in vacuo and the resulting crude is purified by chromatography on silica eluting with ethyl acetate/iso-hexane (1:4 increasing to 1:2) to yield the titled product. 
Organski dijelovi se isperu sa zas. otopinom NaCl, osuše (Na»S04) 1 koncentriraju u vakuumu, a dobiveni sirov proizvod se očisti kromatografijom na stupcu silika gela ispirući s etil acetat/izo-heksanom (1:4 rastući do 1:2), čime se dobije naslovni proizvod.
providing a low molarity shock buffer, wherein the osmolarity of the high molarity slurry is higher than the molarity of the low molarity shock buffer; 
pripremanje šok-pufera niske molarnosti, pri čemu je osmolarnost od emulzije visoke molarnosti, veća nego molarnost od šok-pufera niske molarnosti;
represents linear or branched PEG 20kDa to 80kDa endcapped with a methoxy-group, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation. 
R* predstavlja ravni ili razgranatni PEG 20kDa do 80kDa zaklopljen s metoksi skupinom, ili jedna od njegovih soli, njegovi solvati ili solvati njegovih soli, u kombinaciji s inertnim netoksičnim farmaceutski prikladnim ekscipijentom, pri čemu je lijek u farmaceutskom obliku za inhalaciju.
reacting compound E4 with hydrogen in the presence of acetic anhydride to form compound E5 and 
reagiranje spoja E4 [image] sa vodikom uz prisustvo acetatnog anhidrida čime nastaje spoj E5 [image] i
This invention differs from the prior art in that the combination product of the invention contains, as active principles, a cholinergic agent (which is not an acetylcholinergic effector but an acetylcholinesterase inhibitor), and a connexin-blocking agent. In a preferred embodiment, the combination product of the invention contains, as sole active principles, said acetylcholinesterase inhibitor and said connexin-blocking agent. 
Terapijski kombinacijski produkt tvari koji sadrži najmanje jedno sredstvo koje blokira koneksin i inhibitor acetilkolinesteraze (AChEI), kao kombinacijske produkte za simultanu, odvojenu ili sekvencijalnu upotrebu, za liječenje kognitivnih poremećaja, pri čemu rečeni inhibitor acetilkolinesteraze (AChEl) jest donepezil ili njegova farmaceutska sol.
% based on the outer layer. 
% bazirano na vanjskom sloju; i
The management system as claimed in claim 1, wherein said at least one sensor comprises an oxygen level sensor, an electrical conductivity sensor, temperature sensor and pH sensor. 
Sustav za upravljanje prema patentnom zahtjevu 1 ili 2, naznačen time da navedeni najmanje jedan senzor (24) sadrži senzor razine kisika, senzor električne vodljivosti, temperaturni senzor i pH senzor.
Details of Mitsunobu reactions are contained in Tet. 
Detalji Mitsunobu reakcija sadržani su u Tet.
The assembly according to claims 1 and 2, characterized in that the backing ribbon takeup device comprises, for each rewinding roller (10, 11), a photocell which is capable of detecting that the reel (13, 14) of ribbon being wound onto the rewinding roller (10, 11) has reached the intended size and of consequently causing the actuation of an automatic splicer (15) and the emission of an alert to the assigned operator. 
Uređaj prema zahtjevu 1 12, naznačen time, da prihvatna naprava koja prihvaća povratnu traku, sadrži fotoćeliju za svaki od dva valjka za premotavanje (10, 11), koja je osposobljena za otkrivanje stanja u kojem bubanj za namatanje (13, 14) trake, koji je namotan na valjak za premotavanje (10, 11), dosegne namjeravanu veličinu i tada posljedično uzrokuje pokretanje automatskog spojnog nastavka (15) i emitiranje upozorenja za postavljenog djelatnika.
The liposome of claim 9, wherein the self-replicating RNA molecule has two open reading frames, the first of which encodes an alphavirus replicase and the second of which encodes the immunogen. 
Liposom u skladu s patentnim zahtjevom 9, naznačen time što samoreplicirajuća molekula RNA ima dva otvorena okviri čitanja, od kojih prvi kodira alfavirusnu replikazu, a drugi kodira imunogen.
The cap (104) of any one of claims 1-5, wherein the opening (108) has a profile selected from the group consisting of: a circle, an oval, and an ellipse. 
Poklopac (104) prema barem jednom od prethodnih zahtjeva, naznačen time da otvor (108) ima profil koji je odabran iz skupine koju čine: krug, ovalni oblik, 1 elipsa.
In both samples B and C the dimethylsulfide concentration had been reduced after illumination in comparison to samples A and a significant increase was observed in the concentration of dimethyldisulfide. 
U uzorcima B i C koncentracija dimetilsulfida je bila snižena nakon osvjetljavanja, u usporedbi s uzorcima A, i primijećeno je značajno povećanje koncentracije dimetildisulfida.
In a preferred embodiment, a sustained release composition containing from about 10 to about 15 milligrams of 4-aminopyridine is administered twice daily. 
Sastav prema zahtjevu 1, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 5 do 10 miligrama aminopiridina.
glyphosate salt in solution in the water in an amount greater than 39 weight percent of acid equivalent, based on the weight of the concentrate, said glyphosate salt being selected from the group consisting of the isopropylamine salt of glyphosate, the potassium salt of glyphosate, mixtures of the isopropylamine salt and the potassium salt of glyphosate and mixtures of the potassium salt and the ammonium salt of glyphosate; 
sol glifosata u otopini u vodi u količini većoj od 39 masenih udjela kiselinskog ekvivalenta, na temelju mase koncentrata, navedena sol glifosata je odabrana iz grupe koja se sastoji od izopropilaminske soli glifosata, kalijeve soli glifosta, smjese izopropilaminske soli i kalijeve soli glifosata i smjese kalijeve soli i amonijeve soli glifosata; c. = sustav surfaktanta u količini u rasponu od 1 do 20 masenih udjela, na temelju mase koncentrata, sadrži: i.
A process for the preparation of a camptothecin derivative in which the polymorph Form II of claims 1-4 is used. 
Postupak dobivanja derivata kamptotecina, naznačen time što se u postupku upotrebljava polimorfni Oblik I u skladu s patentnim zahtjevima 1-4.
It is to be understood that when R1 is a group (1-6C)alkyl substituted by, for example amino to give for example a 2-aminoethyl group, it is the (1-6C)alkyl group that is attached to the group X1 (or the quinazoline ring when X1 is a direct bond). 
Podrazumijeva se da kada je R! (1-6C)alkilna skupina supstituirana, na primjer, aminoskupinom pri čemu nastaje 2-aminoetilna skupina, da je baš ta (1-6C)alkilna skupina ona koja je vezana na skupinu X' (ili na kinazolinski prsten kada je X! izravna veza)
brominating the product of step (a) with bromine in a compatible solvent; 
(b) bromiranje proizvoda iz koraka (a) bromom u kompatibilnom otapalu;
condensing (151) said pyrolysis products from said gas mixture (30) in a condensation chamber, obtaining a condensate liquid phase (33), comprising a main amount of the product of pyrolysis that it is separated from the uncondensed gas, such that said organic liquid (33) can be recycled as such to a production process of fiberglass-reinforced plastics as a mixture with commercial unsaturated resins. 
kondenziranje (151) navedenih produkata pirolize iz navedene smjese plinova (30) u komori za kondenzaciju uz dobivanje tekuće faze kondenzata (33), koje uključuje glavnu količinu produkata pirolize, koja se odvaja od nekondenziranog plina na način da se navedena organska tekućina (33) može reciklirati iz
The pharmaceutical composition of any one of claims 1 to 3, wherein n is 1 and Y is C1-8 alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, C1-4alkylamino, or C2-8dialkylamino. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu n je 1 i Y je C1-8 alkilen opcionalno supstituiran s 1, 2 ili 3 halo, OH, CN, amino, C1-4 alkilamino, ili C2-8 dialkilamino.
isopropyl acetate) and the oxidant being in aqueous solution. 
izopropil acetat) a oksidant je u vodenoj otopini.
A device as claimed in claim 13 and wherein the filler opening is coverable by a sliding lid. 
Naprava u skladu s patentnim zahtjevom 13, naznačena time što se otvor za punjenje može pokriti klizećim poklopcem.
an amine, optionally in the presence of an additive selected from an alkaline earth metal halide; 
- < amina, po izboru u prisutsvu aditiva odabranog od zemnoalkalnih metala halida;
an upstream primer and a downstream primer, each comprising a single-stranded DNA molecule of less than 30 nucleotides, at least a portion of which is complementary to a sequence of the target molecule; 
(a) uzvodna početnica i nizvodna početnica, svaka sadrži molekulu jednolančane DNK gdje ima manje od 30 nukleotida, čiji je najmanje jedan dio komplementaran sekvenci ciljane molekule;
A prodrug of the compound of claim 1 . A pharmaceutical composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 7, i farmakološki prihvatljiv nosač.
The mutant FSH of claim 1, wherein N3 of NO: 4 is glycosylated. 
Mutirani FSH prema zahtjevu 1, naznačen time da je ostatak N3 a-podjedinice glikoziliran.
The host organism of claim 1 or 2, wherein the recombinant VKORC1 and the recombinant VKD protein are expressed via an expression mode selected from the group consisting of induced, transient, and permanent expression. 
Organizam domaćina prema zahtjevu 1, naznačen time, da je eksprimirana ili nukleinska kiselina koja kodira za rekombinantni VKORC1 ili nukleinska kiselina koja kodira za rekombinantni VKD-protein ili su obje eksprimirane, i to putem načina ekspresije odabranog iz skupine koju čine inducirana, tranzijentna i permanentna ekspresija.
That is, certain derivatives may be more readily able to take advantage of an available transporter in order to facilitate the passage of the rapamycin carbohydrate derivative out of the gastrointestinal tract and deliver it to the blood stream where the carbohydrate moiety can be cleaved off, thereby releasing rapamycin. 
To jest, neki derivati mogu prije doći do dostupnog prijenosnika kako bi olakšali prijelaz ugljikohidratnog derivata rapamicina iz gastrointestinalnog trakta i prošli u krvotok gdje se ugljikohidratna jedinica može odcijepiti, oslobađajući rapamicin.
An antibody according to claim 12 wherein the constant region is mutated to render the antibody non-lytic. 
Protutijelo u skladu s patentnim zahtjevom 15, naznačeno time što konstantno područje je mutirano, kako bi se protutijelo učinilo nelitičkim.